OncoMed Research Platform
Leveraging a robust and productive scientific platform, we have built a portfolio of active therapeutic compounds that
target biologic pathways critical for the growth, resistance, recurrence, and metastasis of cancer.
Our expertise in isolating and monitoring tumor-initiating cells using specific surface markers and flow cytometry
enables our scientists to evaluate the importance of specific targets implicated in both stem cell biology and cancer.
Antibodies directed against cancer stem cell targets have been developed and tested within proprietary xenograft models
derived from minimally passaged human cancers. We believe these patient-derived models are more representative of the
clinical features of human tumors than the cell line-based models used in traditional cancer research.
Our models also offer the ability to test the effects of therapeutic candidates on human tumors with varied genetic
backgrounds, which in turn facilitates the identification of predictive biomarkers. As our work in cancer immunotherapy
has increased, we have expanded the types of xenograft models we deploy to include syngeneic mouse models and models using
mice with humanized immune systems so that we can better understand the potential range of immune system responses to our
Our platform also includes multiple antibody discovery technologies, a comprehensive
biomarker and translational medicine effort, and proven process development and antibody
cell line development expertise.